Condition: IO-resistant sqNSCLC · Sponsor: Takeda
Lung cancer is one of the most common forms of cancer. One common type is non-small cell lung cancer (NSCLC). NSCLC happens when abnormal cells in the lungs grow too fast. This can stop the lungs from working normally. This study focuses on NSCLC in later stages (advanced). This means that the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery (unresectable). People with unresectable, advanced or metastatic NSCLC often get treatment with immunotherapy and/or platinum-based chemotherapy (such as cisplatin or carboplatin). Immunotherapy helps the body's germ-fighting (immune) system fight cancer. Chemotherapy kills cancer cells or slows their growth. Over time, these treatments may stop working and the cancer can get worse. Researchers are looking for ways to make immunotherapy work better. One approach is to help the immune system recognize cancer more easily by activating certain cells, called T cells, to attack and kill the tumor cells. TAK-928 is designed to attach to T cells in the tumor and make them more active and abundant. This may help the body fight the cancer and destroy tumor cells. The main aim of this study is to learn how well TAK-928 works and compares with the usual treatment (also called standard of care), docetaxel, in adults with unresectable, advanced or metastatic NSCLC. Another aim is to learn how safe TAK-928 is in adults with NSCLC. The participants can be treated for up to 2 years (24 months) depending on h…
This description comes directly from the study's public registry record.
Takeda Contact · 877-825-3327 · medinfoUS@takeda.com
Always discuss trial participation with your own doctor first.
| St. Bernards Healthcare | Jonesboro, Arkansas, United States | Recruiting |
| Memorial Care | Fountain Valley, California, United States | Recruiting |
| Cancer and Blood Specialty Clinic | Los Alamitos, California, United States | Recruiting |
| Translation Research in Oncology- US, INC (TRIO-US) | Torrance, California, United States | Recruiting |
| D & H Cancer Research Center | Margate, Florida, United States | Recruiting |
| BRCR Global | Tamarac, Florida, United States | Recruiting |
| The University of Texas M.D Anderson Cancer Center (MDACC) | Houston, Texas, United States | Recruiting |
| The First Affiliated Hospital of Anhui Medical University | Hefei, Anhui, China | Recruiting |
| Anhui Provincial Cancer Hospital | Hefei, Anhui, China | Not Yet Recruiting |
| Anhui Provincial Hospital | Hefei, Anhui, China | Recruiting |
| Peking University People's Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
+ 33 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07217301